Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Puma

- PMLiVE

AbbVie takes PARP inhibitor into third phase III trial

Veliparib under investigation for use in advanced breast cancer

- PMLiVE

Avastin first biologic backed in EU for resistant ovarian cancer

Roche drug recommended in latest round of CHMP opinions

Shire Basingstoke

Shire spells out why AbbVie takeover is a bad idea

Talks up its growth prospects as an independent company

Shire Basingstoke

Shire turns down takeover offer from AbbVie

Marks third time UK pharma company has turned down AbbVie's advances

- PMLiVE

Pfizer turns to cancer immunotherapies

Signs deal with French company Cellectis

AbbVie closes in on US approval of all-oral hepatitis C regimen

FDA grants priority review to company’s protease inhibitor ABT-450 regimen

- PMLiVE

Pfizer appoints diabetes expert Morris Birnbaum

He takes up post as chief scientific officer for cardiovascular and metabolic diseases

- PMLiVE

AbbVie, Astellas and Roche teams among Communiqué finalists

2014 shortlist also includes MHP, Pegasus, Red Door, Ruder Finn and Virgo

- PMLiVE

Pfizer abandons AZ takeover bid – for now

Deadline for deal passes after four rejected offers

Roche - Basel

CHMP turns down Avastin for brain cancer

Roche set to be denied expanded use for oncology drug in Europe

- PMLiVE

CHMP backs European approval for six new medicines

Recommends drugs by PTC Therapeutics, Roche, Biogen Idec, Octapharma, Alcon and Veloxis Pharma

- PMLiVE

Teva backs laquinimod for MS despite CHMP rejection

EMA confirms negative opinion after re-examination

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links